When was Oak Bio Co founded?

Oak Bio Co was founded in 2021 and raised its 1st funding round 5 years after it was founded.

Where is Oak Bio Co located?

Oak Bio Co is headquartered in United Kingdom.

Is Oak Bio Co a funded company?

Oak Bio Co is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Jun 03, 2026.

When was the latest funding round of Oak Bio Co?

Oak Bio Co's latest funding was a $***** Series A round on Jun 03, 2026, with participation from 4 investors. Its primary sector is Rare Diseases. In United Kingdom, the Rare Diseases sector has seen $152M in funding in 2026 to date.

Where does Oak Bio Co rank among its competitors?

Oak Bio Co ranks 162nd amongst 280 active competitors, of which 77 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Oak Bio Co, which secured $32.5M in Jun, 2026.

Who are the top competitors of Oak Bio Co?

Oak Bio Co's top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, Oak Bio Co secured the most recent funding round in June, 2026.

Oak Bio Co - 2026 Company Profile, Funding & Competitors

Oak Bio Co is a series A company based in United Kingdom, founded in 2021. It operates as a Developer of clinical stage therapies for treating various rare diseases. Oak Bio Co has raised $32.5M in funding from investors like VenBio, Balyasny Asset Management and Janus Henderson Investors. The company has 280 active competitors, including 77 funded and 98 that have exited. Its top competitors include companies like BridgeBio, Alnylam and PTC Therapeutics.

Company Details

Developer of clinical stage therapies for treating various rare diseases. This entity acquires and advances therapeutic candidates previously deprioritized during drug development processes. The pipeline includes antisense oligonucleotide treatments for neurodevelopmental conditions, recombinant human protein therapies for complications of premature birth, and plasma kallikrein inhibitors for ocular conditions. These activities focus on progressing investigative drug programs through late stage clinical trials toward potential regulatory approval and medical application.

Website: oakhillbioholdings.com
Email ID: *****@oakhillbio.com
Phone Number: +44 **********

Key Metrics

Founded Year

2021

Location

United Kingdom

Stage

Series A

Total Funding

$32.5M in 1 round

Latest Funding Round

Series A, Jun 03, 2026, $*****

Investors

VenBio & 3 more

Ranked

162^nd among 280 active competitors

Similar Companies

BridgeBio & 314 more

View Oak Bio Co's full profile

Oak Bio Co has raised a total funding of $32.5M over 1 round. Its latest funding round was a Series A round on Jun 03, 2026 for $*****. 4 investors participated in its latest round. Oak Bio Co has 4 institutional investors.

Here is the list of recent funding rounds of Oak Bio Co:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 03, 2026	5949457	Series A	3903526	7192815	3576403	5776904

Access funding benchmarks and valuations. Sign up today!

View details of Oak Bio Co's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Oak Bio Co include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Oak Bio Co, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, T. Rowe Price & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
9th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	70/100
10th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
162nd	Oak Bio Co 2021, United Kingdom, Series A	Developer of clinical stage therapies for treating various rare diseases	$32.5M	VenBio, Janus Henderson Investors & 2 others	32/100